Slovenian pharmaceutical company Krka reported H1 consolidated net profit of €101.8 million compared to €91.7 million y/y. Operating profit stood at €135.5 million versus €124.1 million in H1 2017. EBITDA grew to €190.9 million from €177.3 million y/y. Consolidated revenue in H1 rose to €680.5 million from €655.1 million a year ago. Krka has been listed on Warsaw Stock Exchange from 2012….
- Poland AM
- Our Products